- Research article
- Open Access
New alternative splicing variants of the ATXN2 transcript
Neurological Research and Practicevolume 1, Article number: 22 (2019)
Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant disorder with progressive degeneration of cerebellar Purkinje cells and selective loss of neurons in the brainstem. This neurodegenerative disorder is caused by the expansion of a polyglutamine domain in ataxin-2. Ataxin-2 is composed of 1312 amino acids, has a predicted molecular weight of 150-kDa and is widely expressed in neuronal and non-neuronal tissues. To date, the putative functions of ataxin-2 on mRNA translation and endocytosis remain ill-defined. Differential splicing with a lack of exons 10 and 21 was described in humans, and additional splicing of exon 11 in mice. In this study, we observed that the molecular size of transfected full-length wild-type ataxin-2 (22 glutamines) is different from endogenous ataxin-2 and that this variation could not be explained by the previously published splice variants alone.
Quantitative immunoblots and qualitative reverse-transcriptase polymerase-chain-reaction (RT-PCR) were used to characterize isoform variants, before sequencing was employed for validation.
We report the characterization of further splice variants of ataxin-2 in different human cell lines and in mouse and human brain. Using RT-PCR from cell lines HeLa, HEK293 and COS-7 throughout the open reading frame of ataxin-2 together with PCR-sequencing, we found novel splice variants lacking exon 12 and exon 24. These findings were corroborated in murine and human brain. The splice variants were also found in human skin fibroblasts from SCA2 patients and controls, indicating that the polyglutamine expansion does not abolish the splicing.
Given that Ataxin-2 interacts with crucial splice modulators such as TDP-43 and modulates the risk of Amyotrophic Lateral Sclerosis, its own splice isoforms may become relevant in brain tissue to monitor the RNA processing during disease progression and neuroprotective therapy.
The expansion of CAG trinucleotide repeats coding for polyglutamine domains in unrelated proteins causes at least nine autosomal dominantly inherited progressive neurodegenerative disorders, including Huntington’s disease and a number of spinocerebellar ataxias. Expanded polyglutamine domains cause neurotoxicity regardless of the specific protein context within which it resides. Nevertheless, the protein context does modulate the vulnerability threshold of specific neuron populations, as evidenced by the distinct clinical and pathological features of the various disorders [1,2,3,4,5]. Spinocerebellar ataxia type 2 (SCA2) is an autosomal dominant movement disorder caused by progressive degeneration of cerebellar Purkinje cells and spinal motor neurons, as well as selective loss of other neurons in the brainstem, spinal ganglia and thalamus [6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]. The underlying protein, which is mutated in SCA2 and also acts as risk factor in the motor neuron degeneration of Amyotrophic Lateral Sclerosis (ALS), has been identified and named ataxin-2 (gene symbol ATXN2) [21,22,23].
The physiological function of ataxin-2 is unknown. It is a protein distributed diffusely throughout the cytoplasm that was at first claimed to be concentrated at the trans-Golgi network but later shown to reside at the rough endoplasmic reticulum or relocalize to stress granules [24,25,26]. It seems to be involved in RNA quality control, with its Pam2 motif mediating its direct association with the cytoplasmic poly(A)-binding protein (PABP) [27, 28], which functions in translation initiation and mRNA decay regulation. Direct interactions between ataxin-2 and target RNAs are mediated by two protein domains named Lsm and Lsm-AD, which associate preferentially with AU-rich transcript sequences and are highly conserved among ataxin-2 orthologues until yeast and plants [29,30,31]. The C-terminus of ataxin-2 can associate with RBFOX1 (also known as A2BP1 or ataxin-2 binding protein 1), a protein containing a ribonucleoprotein motif that is highly conserved among RNA-binding proteins and which was demonstrated to be important for alternative splicing, neural excitability and autism [32,33,34]. Another putative function is related to the endocytic machinery, where proline-rich-domains (PRD) in ataxin-2 associate with SH3 domains of endophilin-A and GRB2, connecting it to the plasma membrane receptors for epidermal growth factor and/or insulin, which influence different cellular pathways beginning with membrane curvature and vesicle internalization [35,36,37]. Interestingly, ataxin-2 is transcriptionally induced by starvation, and also the second member of this stress-response gene family in mammals, named ataxin-2-like (gene symbol ATXN2L), is upregulated at the mRNA and protein level by EGF signalling .
The ataxin-2 gene (NCBI Reference Sequence: NM_002973.4) is composed of 25 exons. The corresponding protein contains 1312 amino acids resulting in a predicted molecular weight of 150-kDa and is widely expressed in neuronal and non-neuronal human tissues . Several studies have reported alternative splicing of ataxin-2. The splice variants were named type II in which exon 10 is lacking (present in human and mouse cDNAs) , type III lacking exon 10 and exon 11 (only seen in mouse) [39, 40] and type IV deficient in exon 21 . Importantly, the alternative splicing of Ataxin-2 in neurons is under control of RBFOX2 and to be modulated by the SCA1 disease protein Ataxin-1 , while in oligodendroglial cells it is controlled by Quaking .
We observed transfected recombinant full length ataxin-2 cDNA to migrate at considerably higher size in Western-blots than endogenous full-length wild-type ataxin-2, with a size difference larger than explained by the known splice variants. Given the importance of alternative splicing in the pathogenesis of the pathogenesis of motor neuron degenerations like ALS and SMA, and given the importance of alternative splice events in the design of antisense-oligonucleotides in the treatment of SCA2 and ALS, we aimed to re-assess the main splicing events. In the present work, we report new splice variants of human and mouse ataxin-2 gene which lack exon 12 and 24.
Materials and methods
Cell culture and transfection procedure
HeLa, HEK293 and COS-7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Invitrogen) supplemented with 10% fetal bovine serum (PAA Laboratories GmbH) under standard conditions. Skin biopsies were taken from SCA2 patients and age matched controls after informed consent with approval of the local ethics committee, and fibroblasts from them were cultured in DMEM supplemented with 15% fetal bovine serum also under standard conditions. Two different lines of patient fibroblast were used, with different CAG expansion sizes: 38 and 41 CAG. HeLa cells were transfected with 10 μg DNA of pCMV-Myc-ataxin-2 plasmid using DreamFect (OZ Bioscience) according to the manufacturer’s instructions and cells were harvested 24 h after transfection. HEK293 and COS-7 cells were transfected using the Metafectene (Biontex) method and the Mirus reagent (Mirus Bio Corporation), respectively, and both harvested 36 h after transfection. Cells were washed twice with ice-cold PBS and suspended in lysis buffer (RIPA-buffer: 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Igepal CA-630 (Sigma), 0.5% sodium deoxycholate, 0.1% SDS, a tablet of protease inhibitor cocktail (Roche), 1 mM PMSF, and 1 mM Na3VO4), lysed for 15 min at 4 °C and clarified by centrifugation at 16,000 g for 20 min. Mouse brain and cerebellum were homogenized in lysis buffer; after 15 min of incubation in lysis buffer, the lysate was clarified by centrifugation as above. All analyses were done at least in duplicate and reproduced.
Lysates were resolved by 8% SDS-PAGE under reducing conditions and transferred to PVDF membranes. Blots were incubated (1:500) with the mouse monoclonal antibody from BD Transduction Laboratories against amino acids 713–904 of ataxin-2 (its specificity was previously established in Atxn2-KO mouse tissue ), and visualized using the ECL method (Pierce). All analyses were done at least in duplicate and reproduced.
Reverse transcriptase-polymerase chain reaction (RT-PCR) for ataxin-2 transcripts
Total RNA from untransfected HeLa and HEK293 cells, human skin fibroblast and mouse brain or cerebellum was isolated using TRIZOL Reagent method (Invitrogen). The generation of cDNA from 5 μg RNA template was carried out with First-Strand cDNA Synthesis Kit (Amersham Bioscience). Human cDNA from cortex, cerebellum and liver were purchased from ClonTech Laboratories, Inc. 0ne μl of the first-strand mixture was added to 50 μl of the PCR mix containing 200 μM of dNTPs and 10 μM of sense and antisense primers (see Table 1). Amplified products were resolved on a 2% agarose-gel, purified using a QIAquick Gel Extraction kit (QIAGEN) and subjected to fluorescent DNA sequencing. All analyses were done at least in duplicate and reproduced.
DNA sequencing and analysis
For the sequencing PCR we used the ABI PRISM Big Dye Terminator v3.0 Ready Reaction Cycle Sequencing Kit (Applied Biosystems) followed by ethanol/ sodium acetate purification. Samples were run in the sequencer ABI PRISM 377 (Applied Biosystems). Data were analysed using the DNASTAR programs Seqman and Megalign, with sequences being compared to the previously published sequence of human (NM_002973, gi:171543894) and mouse (NM_009125, gi: 124244103) ataxin-2.
Endogenous ataxin-2 protein is smaller than the recombinant
We performed Western-blots from non-transfected cells, from different cell lines (monkey fibroblast from kidney cell line COS-7, human epithelial cervical cancer cell line HeLa and human embryonic kidney cell line HEK293) transfected with human wildtype ataxin-2 containing a polyglutamine domain of 22 units [pCMV-Myc-ataxin-2(22)], and also from mouse brain or cerebellum. Endogenous ataxin-2 was consistently smaller by about 15-kDa than the transfected protein whose recombinant episomal cDNA does not undergo any splicing (Fig. 1). There were no significant differences in the molecular weight of ataxin-2 between the different cell types (HeLa, HEK293, and COS-7). The mouse brain protein has a slightly smaller molecular weight than the corresponding protein in the various cell lines, probably due to the absence of the polyglutamine (polyQ) domain. The known splice variants lacking exon 10 with 210 bp and exon 21 with 54 bp cannot explain this size difference.
Ataxin-2 presents two new splice variants
In order to investigate this discrepancy and the existence of additional variants, PCR primers were designed to amplify successive fragments of the ataxin-2 transcript from 5′ to 3′. In RNA from HeLa and HEK293 cells, and mouse brain or cerebellum, the sequencing of RT-PCR amplification bands confirmed the already published splice variants lacking exon 10 and exon 21 (Fig. 2). Two additional bands were amplified between exon 9 and exon 13 (Fig. 2, lane D), and one additional band at the C-terminus of the gene (Fig. 2, lane F), which have not been observed previously either in human (brain, spinal cord, cerebellum, heart and placenta) or in mouse (adult and whole embryos) tissue. Sequencing analysis of these bands, taking into account the GT-AG rule that predicts the junction between donor site and acceptor site , showed two full new exons, exon 12 (Fig. 3) and exon 24 (Fig. 4), as well as part of exon 12 (data not shown) to be lacking from the variant bands. We named these new splice variants type V (exon 12) and type VI (exon 24), to differentiate them from the known variants. To rule out any PCR artefacts, the same PCRs were performed with the plasmid DNA from pCMV-Myc-ataxin-2 (data not shown), yielding no alternative spliced products and confirming the selectivity of the PCR reaction.
The presence of splicing variants is not dependent on the CAG repeat length
The observed new splice variants were found in cells expressing normal or wild-type ataxin-2. To investigate whether the appearance of these splice variants is dependent on the polyglutamine length, we performed the same type of analysis using human skin fibroblasts from SCA2 patients with 38 and 41 polyglutamine expansions in comparison to control fibroblasts. The results showed that the already known splicing of exon 10 (Fig. 5a), as well as the newly observed splicing of exons 12 and 24 occur in both the control and the SCA2 patient mRNA (Fig. 5b and c), indicating that the splicing is not abolished by the CAG expansion in exon 1. This lack of influence of the CAG repeat length on the splicing was corroborated by the observation that all splice variants were present in mouse brain, where endogenous ataxin-2 contains a single glutamine instead of the polyglutamine domain.
Ataxin-2 is present in different tissue in different amounts
It is well known that splice variants could be tissue specific, indicating different functions of the protein for the different tissues. To elucidate whether ataxin-2 splice variants are expressed in different tissues, we compared samples from human cerebral cortex, cerebellum and liver to the previous analysed. We observed that ataxin-2 full length and splice variants are expressed in human cell lines like HEK293, HeLa and human skin fibroblasts but also in human cerebral cortex and to a lesser extent in cerebellum and liver (Fig. 5a, b and c), although the amount used was the same (see GAPDH loading control). These data indicate that although ataxin-2 is expressed ubiquitously in all cells and tissues tested, the amount of expression differs, and so does the presence of the splice variants.
Our data demonstrate the existence of two new alternative splice variants of ataxin-2 transcript, lacking exon 12 and exon 24, expressed in two human cell lines, human skin fibroblasts as well as mouse and human brain. Interestingly, none of the alternatively spliced exons, neither the known exons 10 and 21, nor the newly observed exon 12 and exon 24, contain the established protein motifs described for ataxin-2 (Lsm according to UniProt entry Q99700 at amino acids 265–341 is encoded by exons 3–5, LsmAD at aa 409–476 is encoded by exons (6)-7–8, PAM2 at aa 909–926 is encoded by exon 16), but it is interesting to note that the putative PRD motif at aa 588–593 is encoded by the alternatively spliced exon 10. These data suggest that the alternatively spliced exons code for regulatory fine-tuning, while the invariably spliced exons code for the basic functions of ataxin-2 in RNA metabolism. This fine regulation of basic ataxin-2 function is not abolished by the polyglutamine expansion in patient cells, nor in mouse tissue where ataxin-2 contains one glutamine instead of the human polyglutamine domain. At present, it is impossible to elucidate the functional consequences of the new splicing variants, since functional assays for the physiological role of ataxin-2 are still lacking.
It cannot be decided yet, whether exon splicing, proteolytic events or an alternative translation start site lead to the unexpectedly short size of endogenous ataxin-2. Previous data demonstrating the splicing of exon 10  and exon 21 , and the present data demonstrating the splicing of exon 12 and 24 consistently indicate that the full-length mRNA is always present in a significant amount. Western-blots detect an apparently single band representing the endogenous protein ataxin-2, indicating that size differences due to skipping of an individual exon would not be detectable in a 150 kDa protein, but the parallel skipping of several exons might become detectable. Ataxin-2 mRNA appears to be regulated with enormous complexity, given that (i) ataxin-2 exon 5 as circular RNA is induced 40-fold by Transforming Growth Factor beta under control of the transcription factor Quaking , (ii) ataxin-2 expression is complemented by a long antisense transcript  and (iii) ataxin-2 expression interacts with miRNA regulation . Unfortunately, antibodies with specificity for the alternatively spliced domains of ataxin-2 do not exist, and their design and generation in future experiments would help greatly to identify the functional relevance for each of these ataxin-2 exons.
Recent research has also demonstrated ataxin-2 to act as risk factor in the motor neuron degenerative disease Amyotrophic Lateral Sclerosis (ALS), in RNA-mediated interaction with the splicing modulator TDP-43 [47,48,49,50]. Motor neuron degeneration due to TDP-43 aggregation pathology cannot be rescued by knockdown of TDP-43 itself, in view of the embryonal lethality of TDP-43 mutants, but the knockdown of the ALS risk factor ataxin-2 has been successful in preventing the neurodegenerative process . For the design of such antisense-oligonucleotide-based neuroprotective therapies, the knowledge of alternative splicing patterns is crucial. Precise targeting of antisense oligonucleotides to correct splice events in the SMN gene is responsible for the current therapeutic breakthrough in the prevention of infantile motor neuron degeneration known as Spino-Muscular Atrophy (SMA). Thus, it will be very interesting to study the role of alternative splicing of ataxin-2 and of many TDP-43 dependent splice events throughout the global transcriptome in nervous tissues of ALS models or patients.
Overall, the ataxin-2 transcript encodes a protein with putative functions in mRNA translation and endocytosis, which is consistently shorter than predicted full-length in different human cell lines as well as mouse and human brain. This observation may be partially explained by alternative splicing of exons 10, 12 (novel variant type V), 21 and 24 (type VI).
Cowan, C. M., & Raymond, L. A. (2006). Selective neuronal degeneration in Huntington’s disease. Current Topics in Developmental Biology, 75, 25–71.
Duenas, A. M., Goold, R., & Giunti, P. (2006). Molecular pathogenesis of spinocerebellar ataxias. Brain, 129, 1357–1370.
Orr, H. T., & Zoghbi, H. Y. (2007). Trinucleotide repeat disorders. Annual Review of Neuroscience, 30, 575–621.
Shao, J., & Diamond, M. I. (2007). Polyglutamine diseases: Emerging concepts in pathogenesis and therapy. Human Molecular Genetics, 16(Spec No. 2), R115–R123.
Yamada, M., Shimohata, M., Sato, T., Tsuji, S., & Takahashi, H. (2006). Polyglutamine disease: Recent advances in the neuropathology of dentatorubral-pallidoluysian atrophy. Neuropathology, 26, 346–351.
Lastres-Becker, I., Rüb, U., & Auburger, G. (2008). Spinocerebellar ataxia 2 (SCA2). Cerebellum, 7(2), 115–124.
Rüb, U., Del Turco, D., Del Tredici, K., de Vos, R. A., Brunt, E. R., Reifenberger, G., et al. (2003). Thalamic involvement in a spinocerebellar ataxia type 2 (SCA2) and a spinocerebellar ataxia type 3 (SCA3) patient, and its clinical relevance. Brain, 126(Pt 10), 2257–2272.
Rüb, U., Brunt, E. R., de Vos, R. A., Del Turco, D., Del Tredici, K., Gierga, K., et al. (2004). Degeneration of the central vestibular system in spinocerebellar ataxia type 3 (SCA3) patients and its possible clinical significance. Neuropathol Appl Neurobiol, 30(4), 402–414.
Rüb, U., Bürk, K., Schöls, L., Brunt, E. R., de Vos, R. A., Orozco Diaz, G., et al. (2004). Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxia type 1, 2, and 3. Neurology, 63(7), 1258–1263.
Gierga, K., Bürk, K., Bauer, M., Orozco Diaz, G., Auburger, G., Schultz, C., et al. (2005). Involvement of the cranial nerves and their nuclei in spinocerebellar ataxia type 2 (SCA2). Acta Neuropathologica, 109(6), 617–631.
Rüb, U., Del Turco, D., Bürk, K., Orozco Diaz, G., Auburger, G., Mittelbronn, M., et al. (2005). Extended pathoanatomical studies point to a consistent affection of the thalamus in spinocerebellar ataxia type 2. Neuropathology Applied Neurobiology, 31(2), 127–140.
Rüb, U., Brunt, E. R., Petrasch-Parwez, E., Schöls, L., Theegarten, D., Auburger, G., et al. (2006). Degeneration of ingestion-related brainstem nuclei in spinocerebellar ataxia type 2, 3, 6 and 7. Neuropathology Applied Neurobiology, 32, 635–649.
Rüb, U., Seidel, K., Ozerden, I., Gierga, K., Brunt, E. R., Schöls, L., et al. (2007). Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Research Reviews, 53, 235–249.
Hoche, F., Seidel, K., Brunt, E. R., Auburger, G., Schöls, L., Bürk, K., et al. (2008). Involvement of the auditory brainstem system in spinocerebellar ataxia type 2 (SCA2), type 3 (SCA3) and type 7 (SCA7). Neuropathology Applied Neurobiology, 34(5), 479–491.
Hoche, F., Balikó, L., den Dunnen, W., Steinecker, K., Bartos, L., Sáfrány, E., et al. (2011). Spinocerebellar ataxia type 2 (SCA2): Identification of early brain degeneration in one monozygous twin in the initial disease stage. Cerebellum, 10(2), 245–253.
Scherzed, W., Brunt, E. R., Heinsen, H., de Vos, R. A., Seidel, K., Bürk, K., et al. (2012). Pathoanatomy of cerebellar degeneration in spinocerebellar ataxia type 2 (SCA2) and type 3 (SCA3). Cerebellum, 11(3), 749–760.
Rüb, U., Farrag, K., Seidel, K., Brunt, E. R., Heinsen, H., Bürk, K., et al. (2013). Involvement of the cholinergic basal forebrain nuclei in spinocerebellar ataxia type 2 (SCA2). Neuropathology Applied Neurobiology, 39(6), 634–643.
Rüb, U., Schöls, L., Paulson, H., Auburger, G., Kermer, P., Jen, J. C., et al. (2013). Clinical features, neurogenetics and neuropathology of the polyglutamine spinocerebellar ataxias type 1, 2, 3, 6 and 7. Progress in Neurobiology, 104, 38–66.
Schöls, L., Reimold, M., Seidel, K., Globas, C., Brockmann, K., Hauser, T. K., et al. (2015). No parkinsonism in SCA2 and SCA3 despite severe neurodegeneration of the dopaminergic substantia nigra. Brain, 138(Pt 11, 3316–3326.
Seidel, K., Siswanto, S., Fredrich, M., Bouzrou, M., den Dunnen, W. F. A., Özerden, I., et al. (2017). On the distribution of intranuclear and cytoplasmic aggregates in the brainstem of patients with spinocerebellar ataxia type 2 and 3. Brain Pathology, 27(3), 345–355.
Imbert, G., Saudou, F., Yvert, G., Devys, D., Trottier, Y., Garnier, J. M., et al. (1996). Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nature Genetics, 14, 285–291.
Pulst, S. M., Nechiporuk, A., Nechiporuk, T., Gispert, S., Chen, X. N., Lopes-Cendes, I., et al. (1996). Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nature Genetics, 14, 269–276.
Sanpei, K., Takano, H., Igarashi, S., Sato, T., Oyake, M., Sasaki, H., et al. (1996). Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nature Genetics, 14, 277–284.
Huynh, D. P., Yang, H. T., Vakharia, H., Nguyen, D., & Pulst, S. M. (2003). Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Human Molecular Genetics, 12, 1485–1496.
van de Loo, S., Eich, F., Nonis, D., Auburger, G., & Nowock, J. (2009). Ataxin-2 associates with rough endoplasmic reticulum. Experimental Neurology, 215(1), 110–118.
Kaehler, C., Isensee, J., Nonhoff, U., Terrey, M., Hucho, T., Lehrach, H., & Krobitsch, S. (2012). Ataxin-2-like is a regulator of stress granules and processing bodies. PLoS One, 7(11), e50134.
Ralser, M., Albrecht, M., Nonhoff, U., Lengauer, T., Lehrach, H., & Krobitsch, S. (2005). An integrative approach to gain insights into the cellular function of human ataxin-2. Journal of Molecular Biology, 346, 203–214.
Damrath, E., Heck, M. V., Gispert, S., Azizov, M., Nowock, J., Seifried, C., et al. (2012). ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genetics, 8(8), e1002920.
Satterfield, T. F., & Pallanck, L. J. (2006). Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes. Human Molecular Genetics, 15(16), 2523–2532.
Yokoshi, M., Li, Q., Yamamoto, M., Okada, H., Suzuki, Y., & Kawahara, Y. (2014). Direct binding of Ataxin-2 to distinct elements in 3′ UTRs promotes mRNA stability and protein expression. Molecular Cell, 55(2), 186–198.
Jiménez-López, D., & Guzmán, P. (2014). Insights into the evolution and domain structure of Ataxin-2 proteins across eukaryotes. BioMedCentral Research Notes, 7, 453.
Shibata, H., Huynh, D. P., & Pulst, S. M. (2000). A novel protein with RNA-binding motifs interacts with ataxin-2. Human Molecular Genetics, 9, 1303–1313.
Gehman, L. T., Stoilov, P., Maguire, J., Damianov, A., Lin, C. H., Shiue, L., et al. (2011). The splicing regulator Rbfox1 (A2BP1) controls neuronal excitation in the mammalian brain. Nature Genetics, 43(7), 706–711.
Voineagu, I., Wang, X., Johnston, P., Lowe, J. K., Tian, Y., Horvath, S., et al. (2011). Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature, 474(7351), 380–384.
Nonis, D., Schmidt, M. H., van de Loo, S., Eich, F., Dikic, I., Nowock, J., et al. (2008). Ataxin-2 associates with the endocytosis complex and affects EGF receptor trafficking. Cellular Signalling, 20(10), 1725–1739.
Drost, J., Nonis, D., Eich, F., Leske, O., Damrath, E., Brunt, E. R., et al. (2013). Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling. Journal of Molecular Neuroscience, 51(1), 68–81.
Lastres-Becker, I., Brodesser, S., Lütjohann, D., Azizov, M., Buchmann, J., Hintermann, E., et al. (2008). Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice. Human Molecular Genetics, 17(10), 1465–1481.
Lin, L., Li, X., Pan, C., Lin, W., Shao, R., Liu, Y., et al. (2019). ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance. Cell Death Disease, 10(3), 173.
Nechiporuk, T., Huynh, D. P., Figueroa, K., Sahba, S., Nechiporuk, A., & Pulst, S. M. (1998). The mouse SCA2 gene: cDNA sequence, alternative splicing and protein expression. Human Molecular Genetics, 7, 1301–1309.
Sahba, S., Nechiporuk, A., Figueroa, K. P., Nechiporuk, T., & Pulst, S. M. (1998). Genomic structure of the human gene for spinocerebellar ataxia type 2 (SCA2) on chromosome 12q24.1. Genomics, 47, 359–364.
Affaitati, A., de Cristofaro, T., Feliciello, A., & Varrone, S. (2001). Identification of alternative splicing of spinocerebellar ataxia type 2 gene. Gene, 267, 89–93.
Welzel, F., Kaehler, C., Isau, M., Hallen, L., Lehrach, H., & Krobitsch, S. (2012). FOX-2 dependent splicing of ataxin-2 transcript is affected by ataxin-1 overexpression. PLoS One, 7(5), e37985.
Mandler, M. D., Ku, L., & Feng, Y. (2014). A cytoplasmic quaking I isoform regulates the hnRNP F/H-dependent alternative splicing pathway in myelinating glia. Nucleic Acids Research, 42(11), 7319–7329.
Conn, S. J., Pillman, K. A., Toubia, J., Conn, V. M., Salmanidis, M., Phillips, C. A., et al. (2015). The RNA binding protein quaking regulates formation of circRNAs. Cell, 160(6), 1125–1134.
Li, P. P., Sun, X., Xia, G., Arbez, N., Paul, S., Zhu, S., et al. (2016). ATXN2-AS, a gene antisense to ATXN2, is associated with spinocerebellar ataxia type 2 and amyotrophic lateral sclerosis. Annals of Neurology, 80(4), 600–615.
McCann, C., Holohan, E. E., Das, S., Dervan, A., Larkin, A., Lee, J. A., et al. (2011). The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation. Proc Nat Acad Sci U S A, 108(36), E655–E662.
Elden, A. C., Kim, H. J., hart, M. P., Chen-Plotkin, A. S., Johnson, B. S., Fang, X., et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature, 466(7310), 1069–1075.
Gispert, S., Kurz, A., Waibel, S., Bauer, P., Liepelt, I., Geisen, C., et al. (2012). The modulation of amyotrophic lateral sclerosis risk by ataxin-2 intermediate polyglutamine expansions is a specific effect. Neurobiology of Disease, 45(1), 356–361.
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., et al. (2017). Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature, 544(7650), 367–371.
Auburger, G., Sen, N. E., Meierhofer, D., Başak, A. N., & Gitler, A. D. (2017). Efficient prevention of neurodegenerative diseases by depletion of starvation response factor Ataxin-2. Trends in Neuroscience, 40(8), 507–516.
We are grateful for the support of the staff at our ZFE animal facility, and the technical assistance of Mekhman Azizov.
This work was financially supported by grant LSHM-CT-2004-503304 from the European Union (EUROSCA consortium).
Availability of data and materials
Ethics approval and consent to participate
Approval of the local ethics commissions was obtained to obtain mouse tissues (RP Darmstadt, FK1083) and patient cells (University Hospital Frankfurt/M, 147/07). The patients gave written informed consent.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.